Borderline Personality Disorder: Emerging Symptoms, Evolving Therapies, and the Role of Physical Activity in Treatment
DOI:
https://doi.org/10.12775/QS.2025.43.62343Keywords
Borderline Personality Disorder, Physical Activity, Emerging Symptoms, Atypical Presentations, Psychotherapy, Mentalization-Based Treatment, Personality DisordersAbstract
Background:
Borderline Personality Disorder (BPD) is a complex and heterogeneous mental health condition, traditionally characterized by emotional dysregulation, impulsivity, unstable interpersonal relationships, and a distorted self-image. In recent years, clinical research has increasingly identified atypical symptom presentations and highlighted challenges related to diagnosis, treatment responsiveness, role of physical activity and long-term prognosis.
Aim:
This review aims to provide a comprehensive overview of emerging symptoms associated with BPD, assess the development of novel and evolving therapeutic approaches, role of physical activity in treatment and discuss key prognostic factors that influence clinical outcomes.
Material and Methods:
A systematic literature review was conducted using PubMed as a primary database. Peer-reviewed articles published between 2000 and 2024 were included, with a focus on empirical studies, meta-analyses, and recent clinical guidelines related to BPD symptomatology, treatment, and prognosis.
Conclusions:
Understanding the broader spectrum of BPD symptoms and the dynamic nature of treatment response is essential for accurate diagnosis and effective intervention. An individualized, trauma-informed approach combined with ongoing research into prognostic markers holds promise for improving long-term outcomes in individuals with BPD.
References
Assmann N, Schaich A, Arntz A, et al. The Effectiveness of Dialectical Behavior Therapy Compared to Schema Therapy for Borderline Personality Disorder: A Randomized Clinical Trial [published correction appears in Psychother Psychosom. 2024;93(5):355. doi: 10.1159/000540975.]. Psychother Psychosom. 2024;93(4):249-263. https://doi.org/10.1159/000538404
Baranger DAA, Few LR, Sheinbein DH, et al. Borderline personality traits are not correlated with brain structure in two large samples. Biol Psychiatry Cogn Neurosci Neuroimaging. 2020;5(7):669-677. https://doi.org/10.1016/j.bpsc.2020.02.006
Barnicot K, Crawford M. Dialectical behaviour therapy v. mentalisation-based therapy for borderline personality disorder. Psychol Med. 2019;49(12):2060-2068. https://doi.org/10.1017/S0033291718002878
Bellino S, Bogetto F, Paradiso E, Rocca G, Bozzatello P. Efficacy of omega-3 fatty acids in the treatment of borderline personality disorder: a study of the association with valproic acid. J Psychopharmacol. 2014;28(2):125-132. https://doi.org/10.1177/0269881113510072
Bellino S, Bozzatello P, Rinaldi C, Bogetto F. Paliperidone ER in the Treatment of Borderline Personality Disorder: A Pilot Study of Efficacy and Tolerability. Depress Res Treat. 2011;2011:680194. https://doi.org/10.1155/2011/680194
Bellino S, Bozzatello P, Uscinska M, Bellino S. Efficacy and Tolerability of Asenapine Compared with Olanzapine in Borderline Personality Disorder: An Open-Label Randomized Controlled Trial. CNS Drugs. 2017;31(9):809-819. https://doi.org/10.1007/s40263-017-0458-4
Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of aripiprazole augmentation in sertraline-resistant patients with borderline personality disorder. Psychiatry Res. 2008;161(2):206-212. https://doi.org/10.1016/j.psychres.2007.07.006
Bellino S, Paradiso E, Bozzatello P, Bogetto F. Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study. J Psychopharmacol. 2010;24(3):333-339. https://doi.org/10.1177/0269881108095715
Benedetti F, Sforzini L, Colombo C, Maffei C, Smeraldi E. Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry. 1998;59(3):103-107. https://doi.org/10.4088/jcp.v59n0302
Black DW, Zanarini MC, Romine A, Shaw M, Allen J, Schulz SC. Comparison of low and moderate dosages of extended-release quetiapine in borderline personality disorder: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2014;171(11):1174-1182. https://doi.org/10.1176/appi.ajp.2014.13101348
Bohus M, Stoffers-Winterling J, Sharp C, Krause-Utz A, Schmahl C, Lieb K. Borderline personality disorder. Lancet. 2021;398(10310):1528-1540. https://doi.org/10.1016/S0140-6736(21)00476-1
Bozzatello P, Rocca P, Bellino S. Combination of Omega-3 Fatty Acids and Valproic Acid in Treatment of Borderline Personality Disorder: A Follow-Up Study. Clin Drug Investig. 2018;38(4):367-372. https://doi.org/10.1007/s40261-017-0617-x
Buric I, Vancampfort D, Firth J, Stubbs B. The role of physical activity in borderline personality disorder: A narrative review. Front Psychiatry. 2023;14:1182271. https://doi.org/10.3389/fpsyt.2023.1182271
Burton SW. A review of fluvoxamine and its uses in depression. Int Clin Psychopharmacol. 1991;6 Suppl 3:1-21. https://doi.org/10.1097/00004850-199112003-00001
Cavelti M, Thompson K, Chanen AM, Kaess M. Psychotic symptoms in borderline personality disorder: developmental aspects. Curr Opin Psychol. 2021;37:26-31. https://doi.org/10.1016/j.copsyc.2020.07.003
Chanen AM, Nicol K, Betts JK, Thompson KN. Diagnosis and treatment of borderline personality disorder in young people. Curr Psychiatry Rep. 2020;22(5):25. https://doi.org/10.1007/s11920-020-01144-5
Choi-Kain LW, Sahin Z, Traynor J. Borderline personality disorder: updates in a postpandemic world. Focus (Am Psychiatr Publ). 2022;20(4):337-352. https://doi.org/10.1176/appi.focus.20220057
Crawford MJ, Sanatinia R, Barrett B, et al. The Clinical Effectiveness and Cost-Effectiveness of Lamotrigine in Borderline Personality Disorder: A Randomized Placebo-Controlled Trial. Am J Psychiatry. 2018;175(8):756-764. https://doi.org/10.1176/appi.ajp.2018.17091006
D'Agostino A, Rossi Monti M, Starcevic V. Psychotic symptoms in borderline personality disorder: an update. Curr Opin Psychiatry. 2019;32(1):22-26. https://doi.org/10.1097/YCO.0000000000000462
Degasperi G, Cristea IA, Di Rosa E, Costa C, Gentili C. Parsing variability in borderline personality disorder: a meta-analysis of neuroimaging studies. Transl Psychiatry. 2021;11(1):314. https://doi.org/10.1038/s41398-021-01446-z
de Girolamo G. Exercise-based interventions for patients with borderline personality disorder: A clinical perspective. Int J Psychiatry Clin Pract. 2024;28(1):45-52. https://doi.org/10.1080/13651501.2023.2289978
Del Casale A, Bonanni L, Bargagna P, et al. Current Clinical Psychopharmacology in Borderline Personality Disorder. Curr Neuropharmacol. 2021;19(10):1760-1779. https://doi.org/10.2174/1570159X19666210610092958
Domes G, Ower N, von Dawans B, et al. Effects of intranasal oxytocin administration on empathy and approach motivation in women with borderline personality disorder: a randomized controlled trial. Transl Psychiatry. 2019;9(1):328. Published 2019 Dec 4. https://doi.org/10.1038/s41398-019-0658-4
Fineberg SK, Choi EY, Shapiro-Thompson R, et al. A pilot randomized controlled trial of ketamine in Borderline Personality Disorder. Neuropsychopharmacology. 2023;48(7):991-999. https://doi.org/10.1038/s41386-023-01540-4
Frankenburg FR, Zanarini MC. Clozapine treatment of borderline patients: a preliminary study. Compr Psychiatry. 1993;34(6):402-405. https://doi.org/10.1016/0010-440x(93)90065-c
Francis B, Ganasan VA, Sulaiman ARB. Brexpiprazole attenuates aggression, suicidality and substance use in borderline personality disorder: a case series. Medicina (Kaunas). 2024;60(2):283. https://doi.org/10.3390/medicina60020283
Freeman MP, Hibbeln JR, Wisner KL, et al. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry [published correction appears in J Clin Psychiatry. 2007 Feb;68(2):338]. J Clin Psychiatry. 2006;67(12):1954-1967. https://doi.org/10.4088/jcp.v67n1217
Glaser JP, Van Os J, Thewissen V, Myin-Germeys I. Psychotic reactivity in borderline personality disorder. Acta Psychiatr Scand. 2010;121(2):125-134. https://doi.org/10.1111/j.1600-0447.2009.01427.x
Harty M. Dance movement therapy for emotional regulation in borderline personality disorder: A qualitative case study. Arts Psychother. 2024;84:102132. https://doi.org/10.1016/j.aip.2023.102132
Jones C, Barrera I, Brothers S, Ring R, Wahlestedt C. Oxytocin and social functioning. Dialogues Clin Neurosci. 2017;19(2):193-201. https://doi.org/10.31887/DCNS.2017.19.2/cjones
Jørgensen MS, Møller L, Bo S, et al. The course of borderline personality disorder from adolescence to early adulthood: A 5-year follow-up study. Compr Psychiatry. 2024;132:152478. https://doi.org/10.1016/j.comppsych.2024.152478
Kaazan P, Seow W, Tan Z, et al. Deliberate foreign body ingestion in patients with underlying mental illness: a retrospective multicentre study. Australas Psychiatry. 2023;31(5):619-624. https://doi.org/10.1177/10398562231189431
Kavoussi RJ, Coccaro EF. Divalproex sodium for impulsive aggressive behavior in patients with personality disorder. J Clin Psychiatry. 1998;59(12):676-680. https://doi.org/10.4088/jcp.v59n1206
Kern ML, Becker AE. Physical exercise as an adjunct to psychotherapy in the treatment of borderline personality disorder: A pilot study. J Psychiatr Pract. 2012;18(5):335-340. https://doi.org/10.1097/01.pra.0000416017.80045.2b
Knadler MP, Lobo E, Chappell J, Bergstrom R. Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011;50(5):281-294. https://doi.org/10.2165/11539240-000000000-00000
Lee SS, Allen J, Black DW, Zanarini MC, Schulz SC. Quetiapine's effect on the SCL-90-R domains in patients with borderline personality disorder. Ann Clin Psychiatry. 2016;28(1):4-10.
Leiberich P, Nickel MK, Tritt K, Pedrosa Gil F. Lamotrigine treatment of aggression in female borderline patients, Part II: an 18-month follow-up. J Psychopharmacol. 2008;22(7):805-808. https://doi.org/10.1177/0269881107084004
Leichsenring F, Fonagy P, Heim N, et al. Borderline personality disorder: a comprehensive review of diagnosis and clinical presentation, etiology, treatment, and current controversies. World Psychiatry. 2024;23(1):4-25. https://doi.org/10.1002/wps.21156
Liakopoulou E, Vassalou G, Tzavara C, Gonidakis F. A 12-month study of dialectical behavioral therapy for borderline patients suffering from eating disorders. Eat Weight Disord. 2023;28(1):81. https://doi.org/10.1007/s40519-023-01612-w
Linehan MM, McDavid JD, Brown MZ, Sayrs JH, Gallop RJ. Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2008;69(6):999-1005. https://doi.org/10.4088/jcp.v69n0617
Loew TH, Nickel MK, Muehlbacher M, et al. Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2006;26(1):61-66. https://doi.org/10.1097/01.jcp.0000195113.61291.48
Manford M. Movement and self-awareness: A body-oriented approach to personality disorder. Body Mov Dance Psychother. 2014;9(3):180-191. https://doi.org/10.1080/17432979.2014.918984
Mannarino VS, Pereira DCS, Gurgel WS, et al. Self-embedding behavior in adults: a report of two cases and a systematic review. J Forensic Sci. 2017;62(4):953-961. https://doi.org/10.1111/1556-4029.13359
Markovitz PJ, Wagner SC. Venlafaxine in the treatment of borderline personality disorder. Psychopharmacol Bull. 1995;31(4):773-777.
Mehren A. High-intensity interval cycling in individuals with borderline personality disorder: Effects on emotion regulation and cardiovascular health. Psychiatry Res. 2024;336:115503. https://doi.org/10.1016/j.psychres.2023.115503
Miller AE, Trolio V, Halicki-Asakawa A, Racine SE. Eating disorders and the nine symptoms of borderline personality disorder: a systematic review and series of meta-analyses. Int J Eat Disord. 2022;55(8):993-1011. https://doi.org/10.1002/eat.23731
Moen R, Freitag M, Miller M, et al. Efficacy of extended-release divalproex combined with "condensed" dialectical behavior therapy for individuals with borderline personality disorder. Ann Clin Psychiatry. 2012;24(4):255-260.
Naess A. Physical activity and psychiatric patients: Effects of a training program in patients with personality disorders. Nord J Psychiatry. 1982;36(4):247-254.
New AS, Buchsbaum MS, Hazlett EA, et al. Fluoxetine increases relative metabolic rate in prefrontal cortex in impulsive aggression. Psychopharmacology (Berl). 2004;176(3-4):451-458. https://doi.org/10.1007/s00213-004-1913-8
Nickel MK, Loew TH, Pedrosa Gil F. Aripiprazole in treatment of borderline patients, part II: an 18-month follow-up. Psychopharmacology (Berl). 2007;191(4):1023-1026. https://doi.org/10.1007/s00213-007-0740-0
Nickel MK, Muehlbacher M, Nickel C, et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2006;163(5):833-838. https://doi.org/10.1176/ajp.2006.163.5.833
Norden MJ. Fluoxetine in borderline personality disorder. Prog Neuropsychopharmacol Biol Psychiatry. 1989;13(6):885-893. https://doi.org/10.1016/0278-5846(89)90040-7
Oumaya M, Friedman S, Pham A, Abou Abdallah T, Guelfi JD, Rouillon F. Personnalité borderline, automutilations et suicide: revue de la littérature. Encephale. 2008;34(5):452-458. https://doi.org/10.1016/j.encep.2007.10.007
Paris J. Differential diagnosis of borderline personality disorder. Psychiatr Clin North Am. 2018;41(4):575-582. https://doi.org/10.1016/j.psc.2018.07.001
Peris L, Szerman N, Ruíz M. Eficacia y seguridad de Gabapentina en el Trastorno Límite de Personalidad: estudio abierto de seis meses de duración [Efficacy and safety of gabapentin in Borderline Personality Disorder: a six-month, open-label study]. Vertex. 2007;18(76):418-422.
Perrella C, Carrus D, Costa E, Schifano F. Quetiapine for the treatment of borderline personality disorder; an open-label study. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(1):158-163. https://doi.org/10.1016/j.pnpbp.2006.08.012
Rao S, Broadbear J. Borderline personality disorder and depressive disorder. Australas Psychiatry. 2019;27(6):573-577. https://doi.org/10.1177/1039856219878643
Reich DB, Zanarini MC, Bieri KA. A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder. Int Clin Psychopharmacol. 2009;24(5):270-275. https://doi.org/10.1097/YIC.0b013e32832d6c2f
Reichl C, Kaess M. Self-harm in the context of borderline personality disorder. Curr Opin Psychol. 2021;37:139-144. https://doi.org/10.1016/j.copsyc.2020.12.007
Riegler L, Schuster B, Gerlach AL. Enhancing psychotherapy outcomes in borderline personality disorder through exercise: A pilot RCT. Psychol Med. 2023;53(6):2564-2572. https://doi.org/10.1017/S0033291721004547
Rinne T, van den Brink W, Wouters L, van Dyck R. SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry. 2002;159(12):2048-2054. https://doi.org/10.1176/appi.ajp.159.12.2048
Romero J. Mind–body interventions in BPD: The role of yoga in emotional and somatic regulation. Complement Ther Clin Pract. 2022;48:101603. https://doi.org/10.1016/j.ctcp.2022.101603
Salzman C, Wolfson AN, Schatzberg A, et al. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol. 1995;15(1):23-29. https://doi.org/10.1097/00004714-199502000-00005
Schatzberg AF. New indications for antidepressants. J Clin Psychiatry. 2000;61 Suppl 11:9-17.
Schulz SC, Zanarini MC, Bateman A, et al. Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study. Br J Psychiatry. 2008;193(6):485-492. https://doi.org/10.1192/bjp.bp.107.037903
Setkowski K, Palantza C, van Ballegooijen W, et al. Which psychotherapy is most effective and acceptable in the treatment of adults with a (sub)clinical borderline personality disorder? A systematic review and network meta-analysis. Psychol Med. 2023;53(8):3261-3280. https://doi.org/10.1017/S0033291723000685
Shafie M, Shahmohamadi E, Cattarinussi G, et al. Resting-state functional magnetic resonance imaging alterations in borderline personality disorder: A systematic review. J Affect Disord. 2023;341:335-345. https://doi.org/10.1016/j.jad.2023.09.001
Simeon D, Baker B, Chaplin W, Braun A, Hollander E. An open-label trial of divalproex extended-release in the treatment of borderline personality disorder. CNS Spectr. 2007;12(6):439-443. https://doi.org/10.1017/s1092852900015315
Simeon D, Bartz J, Hamilton H, et al. Oxytocin administration attenuates stress reactivity in borderline personality disorder: a pilot study. Psychoneuroendocrinology. 2011;36(9):1418-1421. https://doi.org/10.1016/j.psyneuen.2011.03.013
Skabeikyte G, Barkauskiene R. A systematic review of the factors associated with the course of borderline personality disorder symptoms in adolescence. Borderline Personal Disord Emot Dysregul. 2021;8(1):12. https://doi.org/10.1186/s40479-021-00151-z
Smits ML, Luyten P, Feenstra DJ, et al. Trauma and Outcomes of Mentalization-Based Therapy for Individuals With Borderline Personality Disorder. Am J Psychother. 2022;75(1):12-20. https://doi.org/10.1176/appi.psychotherapy.20210027
Soler J, Pascual JC, Campins J, et al. Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder [published correction appears in Am J Psychiatry. 2008 Jun;165(6):777]. Am J Psychiatry. 2005;162(6):1221-1224. https://doi.org/10.1176/appi.ajp.162.6.1221
Soloff PH, Cornelius J, George A, Nathan S, Perel JM, Ulrich RF. Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry. 1993;50(5):377-385. https://doi.org/10.1001/archpsyc.1993.01820170055007
St-Amour N, Brunet J, Cailhol L. Feasibility and acceptability of a home-based physical activity program for individuals with borderline personality disorder. BMC Psychiatry. 2024;24(1):42. https://doi.org/10.1186/s12888-023-05296-6
St-Amour N, Cailhol L, et al. Preferences for physical activity formats among adults with borderline personality disorder: A cross-sectional study. Psychiatry Res. 2024;327:115316. https://doi.org/10.1016/j.psychres.2023.115316
St-Amour N, Cailhol L, Leclerc P. Effects of aerobic exercise on affect and arousal in borderline personality disorder: A pilot study. J Psychiatr Res. 2022;153:50-56. https://doi.org/10.1016/j.jpsychires.2022.06.030
Taylor PJ, Hutton P, Wood L. Exercise for adults with borderline personality disorder: A pilot feasibility study. Pilot Feasibility Stud. 2019;5:134. https://doi.org/10.1186/s40814-019-0526-z
Tritt K, Nickel C, Lahmann C, et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol. 2005;19(3):287-291. https://doi.org/10.1177/0269881105051540
Van den Eynde F, Senturk V, Naudts K, et al. Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder. J Clin Psychopharmacol. 2008;28(2):147-155. https://doi.org/10.1097/JCP.0b013e318166c4bf
WALOCH, Kamil, ŁEPIK, Michał, USZOK, Zofia, ROSIAK, Krzysztof, PŁESKA, Kacper, REGUŁA, Kacper, WOJTANIA, Joanna, PIASZCZYŃSKI, Szymon, CZAJKA, Andrzej and SZYMAŃSKI, Bartłomiej. Personality Disorders – a basic information review. Quality in Sport. Online. 5 June 2024. Vol. 20, p. 51457. [Accessed 15 June 2025]. DOI 10.12775/QS.2024.20.51457.
Woodbridge J, Townsend M, Reis S, Singh S, Grenyer BF. Non-response to psychotherapy for borderline personality disorder: A systematic review. Aust N Z J Psychiatry. 2022;56(7):771-787. https://doi.org/10.1177/00048674211046893
Zanarini MC, Frankenburg FR. omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Am J Psychiatry. 2003;160(1):167-169. https://doi.org/10.1176/appi.ajp.160.1.167
Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2001;62(11):849-854. https://doi.org/10.4088/jcp.v62n1103
Zanarini MC, Frankenburg FR, Parachini EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry. 2004;65(7):903-907. https://doi.org/10.4088/jcp.v65n0704
Zanarini MC, Schulz SC, Detke HC, et al. A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2011;72(10):1353-1362. https://doi.org/10.4088/JCP.08m04138yel
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Aleksandra Sokół, Maria Majewska, Marta Ignatiuk-Chilkiewicz, Joanna Kałuska, Katarzyna Nowicka, Klaudia Mościszko, Wiktor Klimek, Dominika Hakało, Adam Rafałowicz, Tomasz Suprun
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 10
Number of citations: 0
